CN101686686A - 鉴别Lyn激酶激活剂的方法 - Google Patents

鉴别Lyn激酶激活剂的方法 Download PDF

Info

Publication number
CN101686686A
CN101686686A CN200880012768A CN200880012768A CN101686686A CN 101686686 A CN101686686 A CN 101686686A CN 200880012768 A CN200880012768 A CN 200880012768A CN 200880012768 A CN200880012768 A CN 200880012768A CN 101686686 A CN101686686 A CN 101686686A
Authority
CN
China
Prior art keywords
test compound
minutes
lyn kinase
substrate
lyn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880012768A
Other languages
English (en)
Chinese (zh)
Inventor
A·雷奥姆
M·萨波里托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melior Pharmaceuticals I Inc
Original Assignee
Melior Pharmaceuticals I Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melior Pharmaceuticals I Inc filed Critical Melior Pharmaceuticals I Inc
Publication of CN101686686A publication Critical patent/CN101686686A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN200880012768A 2007-02-20 2008-02-20 鉴别Lyn激酶激活剂的方法 Pending CN101686686A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89063207P 2007-02-20 2007-02-20
US60/890,632 2007-02-20
PCT/US2008/054361 WO2008103692A2 (en) 2007-02-20 2008-02-20 Methods of identifying activators of lyn kinase

Publications (1)

Publication Number Publication Date
CN101686686A true CN101686686A (zh) 2010-03-31

Family

ID=39710712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880012768A Pending CN101686686A (zh) 2007-02-20 2008-02-20 鉴别Lyn激酶激活剂的方法

Country Status (13)

Country Link
US (1) US20100152215A1 (https=)
EP (1) EP2120581A4 (https=)
JP (1) JP2010518860A (https=)
KR (1) KR20100014480A (https=)
CN (1) CN101686686A (https=)
AU (1) AU2008218765A1 (https=)
BR (1) BRPI0807928A2 (https=)
CA (1) CA2678813A1 (https=)
IL (1) IL200429A0 (https=)
MX (1) MX2009008874A (https=)
NZ (1) NZ579227A (https=)
WO (1) WO2008103692A2 (https=)
ZA (1) ZA200905776B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102507707A (zh) * 2011-10-12 2012-06-20 山东大学 一种检测正畸牙根吸收的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
EP2790704B1 (en) * 2011-12-12 2019-04-03 Melior Pharmaceuticals I, Inc. Treatment of type i diabetes
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
WO2015099094A1 (ja) 2013-12-27 2015-07-02 国立大学法人東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
US20210106581A1 (en) * 2018-02-21 2021-04-15 Melior Pharmaceuticals I, Inc. Treatment Of Liver Diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3922345A (en) * 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
US4080454A (en) * 1976-07-16 1978-03-21 Pfizer Inc. 5-M-Tolyloxyuracil, anti-ulcer agent
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
US6900304B2 (en) * 1996-01-31 2005-05-31 The Regents Of The University Of California Emission ratiometric indicators of phosphorylation
US20020019346A1 (en) * 1997-05-21 2002-02-14 Children's Medical Center Corporation Treatment of prostate cancer by inhibiting lyn tyrosine kinase
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
GB0104422D0 (en) * 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
CA2524221A1 (en) * 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
EP1541694A1 (en) * 2003-12-12 2005-06-15 Sirenade Pharmaceuticals AG Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase
US20060035302A1 (en) * 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
MX2007006230A (es) * 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
ITUD20050112A1 (it) * 2005-07-01 2007-01-02 Gaetano Azzolina Dispositivo di assistenza cardiocircolatoria
TWI273177B (en) * 2005-07-08 2007-02-11 Ama Precision Inc Fan apparatus with adapting device
WO2007016975A1 (en) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Kinase and phosphatase assays based on fret
JP5113752B2 (ja) * 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102507707A (zh) * 2011-10-12 2012-06-20 山东大学 一种检测正畸牙根吸收的方法
CN102507707B (zh) * 2011-10-12 2015-10-21 山东大学 一种检测龈沟液中蛋白裂解酶含量的方法

Also Published As

Publication number Publication date
JP2010518860A (ja) 2010-06-03
MX2009008874A (es) 2009-10-20
WO2008103692A2 (en) 2008-08-28
BRPI0807928A2 (pt) 2014-07-08
WO2008103692A3 (en) 2008-10-23
NZ579227A (en) 2012-11-30
ZA200905776B (en) 2010-05-26
EP2120581A2 (en) 2009-11-25
EP2120581A4 (en) 2011-03-16
CA2678813A1 (en) 2008-08-28
US20100152215A1 (en) 2010-06-17
KR20100014480A (ko) 2010-02-10
AU2008218765A1 (en) 2008-08-28
IL200429A0 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
Yan et al. Insights into current tropomyosin receptor kinase (TRK) inhibitors: development and clinical application
US8268837B2 (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
CN101686686A (zh) 鉴别Lyn激酶激活剂的方法
JP6568060B2 (ja) 黒色腫の治療のための組合せ医薬
Kowalchuk et al. Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons
CN103764144B (zh) Pi3k抑制剂与mek抑制剂的协同组合
JP2001302547A (ja) 女性の性機能不全を処置するための組成物および方法
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
JP2018090566A (ja) 非小細胞肺癌の治療のためのｅｇｆｒ ｔ７９０ｍ阻害剤およびｃｄｋ阻害剤の組合せ
Irvine et al. Treatment‐, patient‐, and disease‐related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
TW200526224A (en) Short form c-Maf transcription factor antagonists for treatment of glaucoma
KR20240165963A (ko) Tyk2 억제제 및 이의 용도
TW202233193A (zh) 包含ｆｌｔ３抑制劑的用於治療白血病的藥物組合物
AU2025223785A1 (en) 1-(4-{[4-(Dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
JPH11501051A (ja) 強迫性障害、睡眠時無呼吸、性的機能障害、嘔吐および乗物酔いの処置を意図する医薬
US20090074676A1 (en) Inhibition of p38 MAPK For Treatment Of Obesity
Abduelkarem et al. Diarylamides in anticancer drug discovery: A review of pre-clinical and clinical investigations
JP2020045339A (ja) がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
US20090259054A1 (en) Methods and Compositions for the Treatment of Angiogenesis and Macular Degeneration
AU2024329573A1 (en) Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
JP2020536929A (ja) Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物
CN118973583A (zh) Tyk2抑制剂及其用途
Phillips Pruritus: What to do when the itching won't stop

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100331